Arsenic trioxide as first-line treatment for acute promyelocytic leukemia

American Journal of Health-System Pharmacy

Volumn 66, Issue 21, 2009, Pages 1913-1918

  Leu, Lily ^a   Mohassel, Leila ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Antineoplastic agents; Arsenic trioxide; Combined therapy; Dosage; History; Leukemia; Mechanism of action; Toxicity; Tretinoin

Indexed keywords

ANTHRACYCLINE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; ARSENIC; ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; GEMTUZUMAB OZOGAMICIN; HOMOHARRINGTONINE; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CELL DIFFERENTIATION; CHEMOTHERAPY INDUCED EMESIS; CHROMOSOME 15; CHROMOSOME 17; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GENE FUSION; HISTORY OF MEDICINE; HUMAN; HYPERBILIRUBINEMIA; LEUKEMIA; LEUKOCYTOSIS; LIVER DYSFUNCTION; LIVER TOXICITY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QT PROLONGATION; RETINOIC ACID SYNDROME; REVIEW; SIDE EFFECT;

EID: 70449637501     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080342     Document Type: Review

References (24)

1. National Cancer Institute. Adult acute myeloid leukemia treatment (PDQ): classification: acute myeloid leukemia with characteristic genetic abnormalities. www.cancer.gov/cancertopics/pdq/treatment/adultAML/ HealthProfessional/page3#Section-119 (accessed 2008 May 10).
2. Soignet S, Fleischauer A, Polyak T et al. All-trans retinoic acid significantly increased 5-year survival in patients with acute promyelocytic leukemia: long-term follow up of New York study. Cancer Chemother Pharmacol. 1997; 40(suppl):S25-9.
3. Slack JL, Waxman S, Tricot G et al. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. Oncologist. 2002; 7(suppl 1):1-13. (Pubitemid 34293055)
4. Tallman MS, Nabhan C, Feusner JH et al. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 2002; 99:759-767
5. 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2004; 101:5328-5335 (Pubitemid 38481160)
6. Zhang TD. [Treatment of acute granulocytic leukemia with "Ai ling no. 1" - clinical analysis and experimental research.] Zhong Xi Yi Jie He Za Zhi. 1984; 4:19-20. In Chinese.
7. Zhang TD. Leukemia treatment in traditional Chinese medicine. J Tradit Chin Med. 1985; 10:13-14
8. Zhang P, Wang SY, Hu LH et al. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol. 1996; 2:58.
9. Shen ZX, Chen GQ, Ni JH et al. Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997; 89:3354-3360
10. Niu C, Yan H, Yu T et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999; 94:3315-3324 (Pubitemid 29536124)
11. Soignet SL, Maslak P, Wang ZG et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998; 339:1341-1348 (Pubitemid 28509343)
12. Shalabi AM, Fallavollita A, Cheson BD et al. Arsenic trioxide in relapsed or refractory acute promyelocytic leukemia: an NCI special exception (compassionate use) program. Blood. 2001; 98:596a. Abstract. (Pubitemid 33789757)
13. Soignet SL, Frankel SR, Douer D et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001; 19:3852-3860 (Pubitemid 32880064)
14. 3) in the treatment of patients with acute promyelocytic leukemia: the M.D. Anderson experience. Cancer. 2003; 97:2218-2224
15. 3) in the treatment of acute promy- elocytic leukemia. J Biol Regul Homeost Agents. 1999; 13:195-200. (Pubitemid 30742092)
16. Wang SJ. Metals poisoning. 2nd ed. Beijing: People's Medical Publishing House; 1988:151-166
17. Dai J, Weinberg RS, Waxman S et al. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood. 1999; 1:268-277 (Pubitemid 29019412)
18. Chen GQ, Zhou L, Styblo M et al. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res. 2003; 63:1853-1859 (Pubitemid 36460848)
19. Barbey JT, Singer JW, Unnikrishnan D et al. Cardiac toxicity of arsenic trioxide. Blood. 2001; 98:1632-1634
20. Huan SY, Yang CH, Chen YC. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy. Leuk Lymphoma. 2000; 38:283-93.
21. Douer D, Tallman MS. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol. 2005; 23:2396-2410 (Pubitemid 46218734)
22. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol. 2006; 17:131-134 (Pubitemid 43033852)
23. Mathews V, Balasubramanian P, Shaji RV et al. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. Am J Hematol. 2002; 70:292-299 (Pubitemid 34810506)
24. Estey E, Guillermo GM, Alessandra F et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006; 107:3469-3473